Cerora closes seed funding at $600,000

Cerora, a health startup, has closed its seed round for the second time, with funding now totalling $600,000. Investors joining the round are the Brewer Group, Amarantus Bioscience Holdings and Marvin Cadwell, a health service executive.

The money will support the startup’s aim to bring Qumpass, its first product, to market in August 2014, as well as advance development of its other project, Borealis.

Cerora is working on both software and hardware technologies for healthcare professionals. Its products aim to deliver objective, quick and portable diagnostic tools for professionals to diagnose athletes’ concussions on the field. Its software makes use of existing hardware solutions such as Google Glass.

The startup is based at Ben Franklin Technology Partners of Northeastern Pennsylvania’s TechVentures on Lehigh University’s Mountaintop Campus in Bethlehem, Pennsylvania. Its researchers have collaborated extensively with the university’s Sports Medicine department.

Adam Simon, president and chief executive at Cerora, said: “Objective data, rapidly provided near the athletic field, would empower field clinicians evaluating concussions with a considerable diagnostic advantage over current assessment techniques. By empowering field clinicians with objective real-time brain health information, as opposed to subjective clinical impressions, Cerora will improve health outcomes for patients. With these investor commitments to Cerora in hand, our development and commercialisation plans can now shift into high gear.”